Business
Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 - 9, 2025
Company to present at session titled “Personalizing Sepsis Treatment” T...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025\n\n\n\n\n\n\n Company to present at session titled “Personalizing Sepsis Treatment”\n \n\n\n\n\n\n TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) --\n \n Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),\n \n a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its sponsorship of the Unite for Sepsis Symposium, taking place September 8 – 9, 2025, in Chicago, Illinois. The Company also announced that Debra Foster, Clinical Consultant at Spectral Medical, will participate in a featured session during the event.\n \n\n Ms. Foster will contribute to the session titled “Personalizing Sepsis Treatment”, scheduled for Day 1 at 4:15 PM CT, which will highlight how individualized approaches may support earlier intervention and improved outcomes in sepsis care.\n \n\n The Unite for Sepsis Symposium is a unique, in-person event convening an extraordinary community of clinicians, researchers, regulators, investors, innovators, and advocates. More than a symposium, Unite for Sepsis is a collaborative movement dedicated to transforming the way sepsis is prevented, diagnosed, and treated.\n \n\n For more information or to register, please visit\n \n UniteforSepsis.org\n \n\n\n\n About Spectral\n \n\n\n Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood.\n \n\n PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 pati...